Using a combination of pretreatment PSA, tumor stage and Gleason score, the 5-year outcome appears to be similar among men with low-risk and intermediate-risk prostate cancer, regardless of the type of treatment received, researchers report in the November 15th issue of Cancer.
“It is possible to give patients realistic comparisons of the differences in the 5-year rates of biochemical control of prostate cancer with various forms of treatment,” lead author Dr. Frank A. Vicini from the William Beaumont Hospital, Royal Oak, Michigan, told Reuters Health. “Since there are no randomized trials available, the best we can do is to compare retrospective results,” he added.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!